• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Adjuvant hormone therapy may improve survival in ovarian cancer

byMonica ParksandDavid Wang
October 17, 2015
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In a phase III trial of 150 patients with epithelial ovarian cancer, the use of adjuvant hormone therapy was associated with an increase in overall survival compared to the control group.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Ovarian cancer remains as the most common cause of gynecological cancer-related mortality among women worldwide. Definitive surgical ovarian cancer treatment in pre-menopausal women results in premature menopause and an increased risk for vasomotor symptoms, coronary heart disease, and osteoporosis. While hormone replacement therapy (HRT) can reduce these adverse effects, there is uncertainty whether HRT may increase the risk of ovarian cancer relapse. The purpose of the Adjuvant Hormone Therapy (AHT) trial was to evaluate the impact of HRT on survival in patients with ovarian cancer.

This trial randomized 150 ovarian cancer patients to receive either HRT or placebo. At the conclusion of the trial, the patients in the HRT group demonstrated significant increased overall and relapse-free survival compared to the control group. The effect remained after adjusting for known prognostic factors such as disease stage and residual tumor bulk. The results of this study support the use of HRT for patients who demonstrate severe menopausal symptoms after ovarian cancer treatment. This is the largest randomized trial assessing the use of hormone therapy among women with ovarian cancer, and has broad implications for the long-term management of these patients and treatment options to improve their quality of life. However, the study is limited by the relatively small sample size, which did not meet its original recruitment goals. Additional large randomized trials may be required to confirm this association.

Click to read the study in JCO

Relevant Reading: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative

In-Depth [randomized controlled trial]: The Adjuvant Hormone Therapy (AHT) trial was a phase III, multi-center, randomized controlled trial that compared the use of HRT versus control in patients with epithelial ovarian cancer. The study recruited a total of 150 patients. Of these, 34 were premenopausal and 116 were postmenopausal. The primary end point was overall survival (OS) from randomization to death of any cause. Secondary end points included relapse-free survival (RFS), compliance to hormone treatment, and frequency of adverse events (myocardial infarction, fracture, transient ischemic attack, cerebrovascular accident, second cancer). At a median follow up of 19.1 years with intention to treat analysis, OS was superior in the HRT group (HR: 0.63; 95% CI: 0.44-0.9, p=0.011) compared to control. Interestingly, RFS was superior in the HRT group (HR: 0.67; 95% CI: 0.47-0.97, p = 0.032). Adverse event rates were low in both the HRT (12%) and control group (16%) with no significant difference between study arms (p=0.64).

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

#VisualAbstract: Delayed receipt of adjuvant hormone therapy is associated with worse survival in HR⁺, ERBB2- breast cancer

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hormone therapyovarian cancer
Previous Post

Budesonide linked with decreased bronchopulmonary dysplasia in preterm infants

Next Post

Maternal midpregnancy glucose linked to increased risk of congenital heart disease

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

June 30, 2022
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
#VisualAbstract: Delayed receipt of adjuvant hormone therapy is associated with worse survival in HR⁺, ERBB2- breast cancer
StudyGraphics

#VisualAbstract: Delayed receipt of adjuvant hormone therapy is associated with worse survival in HR⁺, ERBB2- breast cancer

March 8, 2022
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Chronic Disease

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

February 15, 2022
Next Post
Maternal midpregnancy glucose linked to increased risk of congenital heart disease

Maternal midpregnancy glucose linked to increased risk of congenital heart disease

Uterus transplant recipients report good psychological outcomes

First stage of labor models show promise in predicting complications

Girls with familial breast cancer history are well-adjusted

Girls with familial breast cancer history are well-adjusted

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.